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1. Introduction 
Bone tissue is the component of the skeletal system that provides the supporting structure 
for the body. Bone has a complex morphology; it is a specialized connective tissue 
composed of a calcified matrix and an organic matrix. The tissue can be organized in either 
the dense (compact) or spongy form (cancellous), with pore sizes within the wide range of 1-
100 µm (Lane et al., 1999). Although the shape of bone varies in different parts of the body, 
the physicochemical structure of bone for these different shapes is basically similar. The 
biochemical composition of bone is precisely composed of two major phases at the 
nanoscale level namely, organic  and inorganic as a good example for a composite. These 
phases have multiple components which consist of, in decreasing proportions, minerals, 
collagen, water, non-collagenous proteins, lipids, vascular elements, and cells (Murugan & 
Ramakrishna, 2005). An overall composition of the bone is given in Table 1. 
 
Inorganic Phases Wt% Bioorganic phases Wt% 
Calcium 
Phosphates 
(biological apatite) 
~ 60 Collagen type Ι ~ 20 
Water ~ 9 
None-collagenous 
proteins 
~ 3 
Carbonates ~ 4 Primary bone cells Balance 
Citrates ~ 0.9 Other traces Balance 
Sodium ~ 0.7 
  Magnesium ~ 0.5 
Other traces Balance 
Table 1. The biochemical composition of bone (Murugan & Ramakrishna, 2005). 
The mineral fraction of bone consists of significant quantities of non-crystalline calcium 
phosphate compounds and predominantly of a single phase that closely resembles that of 
crystalline hydroxyapatite (Ca10(PO4)6(OH)2) (Hench & Wilson, 1993; Dorozhkin, 2010a). 
Biological hydroxyapatite also contains other impurity ions as Cl, Mg, Na, K, and F and 
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trace elements like Sr and Zn (LeGeros, 2002). The apatite in bone mineral is composed of 
small platelet-like crystals of just 2 to 4 nm in thickness, 25 nm in width, and 50 nm in length 
(Dorozhkin & Epple, 2002). Bone mineral non-stoichiometry is primarily due to the presence 
of divalent ions, such as CO32- and HPO42-, which are substituted for the trivalent PO43- ions. 
Substitutions by CO32- and HPO42- ions produce a change of the Ca/P ratio, resulting in 
Ca/P ratio which may vary between 1.50 to 1.70, depending on the age and bone site 
(Raynaud et al., 2002). When a loss of bony tissue occurs as a result of trauma or by the 
excision of diseased, healing requires the implantation of bone substitutes. There is a high 
clinical request for synthetic bone substitution materials, due to the drawbacks  such as a 
prolonged operation time and donor site morbidity in about 10–30% of the cases associated 
with biological bone grafts (Giannoudis et al., 2005; Beaman et al., 2006; Chu et al., 2007). 
Biological grafts are generally associated with potential infections. In order to avoid the 
problems associated with biological bone grafting, there has been a continuous interest in 
the use of synthetic bone substitute materials. Bioactive ceramics such as calcium 
phosphates offer alternatives to synthetic bone substitute (Vallet-Regı & lez-Calbet, 2004; 
Best et al., 2008; Rabiee et al., 2008a). These biomateials with a porous structure not only 
possess good biocompatibility but also allow the ingrowth of tissues and penetration of 
biological fluids and form a chemical bond with bone (Lu & Leng, 2005; Rabiee et al. 2008b). 
Moreover, the Calcium phosphates are freely formed and easily fabricated to satisfy the 
demands for huge bone and large quantities of bone for bone substitute. For these reasons, 
the Calcium phosphates have been considered as useful materials for bone repair and 
replacement. To fabricate a bioactive ceramic bone substitute with various porous 
configuration, the evidence of tissues ingrowth and biological responses provide obvious 
advantages in tissue-implant fixation and controlled biodegradation rate for both short-term 
and long-term implantation purposes (Karageorgiou & Kaplan, 2005, Rabiee et al. 2008b). 
Many processing technologies have been employed to obtain porous calcium phosphates as 
bone filler (Rabiee et al., 2007; Best etal. 2008). For example, porous calcium phosphates can 
be obtained by merging the  slurry with a polymer sponge-like mold or polymer beads 
before sintering. During the sintering, the polymer is completely burnt out, which results in 
a porous structure. The use of highly porous calcium phosphate induces bone formation 
inside the implant and increases degradation. Cortical bone has pores ranging from 1 to 100 
μm (volumetric porosity 5 to 10%), whereas trabecular bone has pores of 200 to 400 μm 
(volumetric porosity 70 to 90%). Porosity in bone provides space for nutrients supply in 
cortical bone and marrow cavity in trabecular bone. Microporosity covers pores sizes 
smaller than 5 μm for penetration of fluids and  Pores larger than 10 μm can be considered 
as macropores. Macroporous dimensions are reported to play a role in osteoinductive 
behavior of bone substitutes (Karageorgiou & Kaplan, 2005; Rabiee et al., 2009). Because of 
the influence of bioactive ceramics on cell behaviour, the bone forming cells are often 
introduced into these porous ceramics to speed-up tissue ingrowth. The surface of bioactive 
ceramics is a good substrate for seeding cells (Cao et al., 2010; Rungsiyakull et al., 2010). 
Bone Tissue engineering typically involves coupling osteogenic cells and/or osteoinductive 
growth factors with bioactive scaffolds (Buma et al., 2004; Mistry & Mikos, 2005). Some 
studies have investigated the bone forming capacities of growth factors loaded synthetic 
bone substitutes. In terms of growth factors, most research has focused on the use of the 
bone morphogenic proteins (BMPs) (Mont et al. 2004; Termaat et al., 2005). They are 
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signalling molecules which can induce de novo bone formation at orthotopic and 
heterotropic sites (Boix et al., 2005). Current examination of alternatives to grafting 
techniques suggests three possible new approaches to inducing new bone formation: 
implantation of certain cytokines such as BMPs in combination with appropriate delivery 
systems at the target site (Liu et al., 2007; Niu et al., 2009); transduction of genes encoding 
cytokines with osteogenic capacity into cells at repair sites; and transplantation of cultured 
osteogenic cells derived from host bone marrow (Chu et al., 2007). BMPs have crucial roles 
in growth and regeneration of skeletal tissues (Nie & Wang, 2007). One primary role of 
BMPs is to regulate the key elements in the bone induction cascade required for 
regeneration of skeletal tissues (Schneider et al., 2003). BMPs are bone matrix protein that 
stimulate mesenchymal cell chemotaxis and proliferation, and promotes the differentiation 
of these cells into chondrocytes and osteoblasts (Calori et al., 2009; Nie & Wang, 2007). This 
osteoinductive action of BMPs is well established to be beneficial during the repair bone 
defects (Termaat et al., 2005).  BMPs act locally and therefore must be delivered directly to 
the site of regeneration via a carrier (Hartman et al., 2005; Chu et al., 2007). Bioactive 
ceramics can act as vehicle for factor delivery to the surrounding tissues. Future research 
should be investigated the potentials of these constructs to find a successful alternative for 
biological bone substitute. 
2. Bioactive ceramics 
Bioactive ceramics are used in a number of different applications in implants and in the 
repair and reconstruction of diseased or damaged body parts. Most medical applications of 
bioactive ceramics relate to the repair of the skeletal system and hard tissue. They include 
several major groups such as calcium phosphate ceramics, bioactive glasses and glass-
ceramics. 
2.1 Calcium phosphate ceramics 
Calcium phosphate ceramics are very popular implants for medical applications because 
of  their similarity to hard tissue. These bioceramics have been synthesized and used for 
manufacturing various forms of implants, as well as for solid or porous coatings on other 
implants. Calcium phosphate compounds exist in several phases. Most of these 
compounds are used as raw material for synthesis of bioactive ceramics.  Different types 
of calcium phosphate are employed to fabricate implants to accommodate bone tissue 
regeneration. Table 2 lists the main Ca-P compounds for biomedical applications (Vallet-
Regı & lez-Calbet, 2004). The atomic ratio of Ca/P in calcium phosphates can be varied 
between 2 and 1 to produce compounds ranged from calcium tetraphosphate(TTCP) 
Ca4P2O9, hydroxyapatite (HA) Ca10(PO4)6(OH)2, octacalcium phosphate (OCP) 
Ca8H2(PO4)6.5H2O, tricalcium phosphate (TCP) Ca3(PO4)2 to dicalcum phosphate 
dihydrate (DCPD) CaHPO4.2H2O or dicalcum phosphate anhydrus (DCPA) CaHPO4. 
(Raynaud et al., 2002; Vallet-Regı & lez-Calbet, 2004; Dorozhkin, 2010b). Due to their high 
solubility, the calcium phosphates compounds with a Ca/P ratio less than 1 are not 
suitable for biological implantation. Hydroxyapatite with Ca/P ratio of 1.667 is much 
more stable than other calcium phosphates. Under physiological conditions, calcium 
phosphates degrade via dissolution–reprecipitation mechanisms (Raynaud et al., 2002). 
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When the dissolution of calcium phosphate is higher than the rate of mineral 
reprecipitation and tissue regeneration, it is not suitable as a good bone substitute. The 
dissolution process is dependent on the nature and their thermodynamic stability of 
calcium phosphate substrate, for example (in order of increasing solubility), HA > TCP > 
OCP > DCPD or DCPA (Bohner, 2000; Dorozhkin, 2010a). In an ideal situation, a 
biodegeradable bone substitute is slowly resorbed and replaced by natural bone. TCP 
with Ca/P ratio of 1.5 is a biodegradable and more resorbed than HA. The use of a 
mixture of HA and β-TCP, as biphasic calcium phosphate (BCP), has been attempted as 
bone substitute. The dissolution and resorption rate of BCP can be controlled with ratio of 
β-TCP/HA (Detsch et al., 2008; De Gabory et al., 2010). 
 
Name Ca/P Formula Acronym 
Calcium Dihydrogen Phosphate 0.5 Ca(H2PO4)2H2O MCP 
Dicalcum phosphate dihydrate 1 CaHPO4.2H2O DCPD 
Dicalcum phosphate anhydrous 1 CaHPO4 DCPA 
Octacalcium phosphate 1.33 Ca8H2(PO4)6.5H2O OCP 
Tricalcium phosphate 1.5 Ca3(PO4)2 TCP 
Hydroxyapatite 1.67 Ca10(PO4)6(OH)2 HA 
Tetracalcium phosphate 2 Ca4O(PO4)2 TTCP 
Table 2. Varius calcium phosphate with their respective Ca/P atomic ratios (Vallet-Regı & 
lez-Calbet, 2004). 
The major limitation to use calcium phosphates is their mechanical properties. Calcium 
phosphates are used primarily as fillers and coatings (Ooms et al., 2003) because they are 
brittle with poor fatigue resistance (Teoh, 2000). 
2.2 Calcium phosphate cements  
Calcium phosphate cements (CPCs) are of interest for bone tissue engineering purposes. 
Different studies with CPCs have shown that they are highly biocompatible and 
osteoconductive materials, which can stimulate tissue regeneration (Bohner, 2000; Carey et 
al., 2005; Ginebra et al., 2006). The main difference between cements when compared to 
other bioactive ceramics, in the form of ceramic granules or bulk materials, is the 
injectability and in-situ hardening. Calcium phosphate cements consist of a powder phase 
and an aqueous liquid, which are mixed together to form a paste that sets after being 
implanted within the body. Brown and Chow prepared the first CPBC in 1985 contained 
TTCP and DCPA or DCPD as the solid phase (Brown & Chow, 1985). After mixing with 
water, the cement components results precipitation of apatite (AP: Ca10-x (HPO4)x(PO4)6-
x(OH)2-x , where 0≤ x ≤2) (Ginebra et al., 2006; Rabiee et al., 2010). There are a variety of 
different combinations of calcium compounds which are used in the formulation of these 
bone cements. In general there are two types of CPC: apatite cements and brushite cements. 
Brushite cement has a lower mechanical strength but a faster biodegradability than the 
apatite cement. Both types of cement can be applied for bone tissue engineering purposes. 
(Carey et al., 2005; Rabiee et al., 2010). CPCs as drug delivery systems, where the drugs can 
be incorporated throughout the whole cement volume. CPCs are suitable materials for local 
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delivery systems in osseous tissue since they can simultaneously promote bone regeneration 
and prevent infectious diseases by releasing therapeutic agents. Recent advances in CPC 
technology have resulted in the enhancement of the handling, application and 
osteoconductive properties of these cements. These improvements have permitted CPCs to 
be assayed as carriers for local delivery of drugs and biologically active substances (Ginebra 
et al., 2006). Drugs, such as antibiotics, antitumors, and growth factors, have been 
administered to defect regions to induce therapeutic effects (Ginebra et al., 2006; Chu et al. 
2007). The success of this idea was favored by the easy incorporation of pharmaceutical and 
biological substances into the cement solid or liquid phases, the intimate adaptation of the 
cement paste to bone defects and permits the release of the entrapped substance to the local 
environment.  
2.3 Bioactive glasses & glass-ceramics  
Bioactive glasses and glass-ceramics have the ability to bind to hard tissues as was 
discovered by Hench in 1969 (Hench, 2006). They are used as implants to repair or replace 
parts of the body; long bones, vertebrae, joints, and teeth. Their clinical success is due to 
formation of a stable, mechanically strong interface with bone (Hench & Wilson, 1993; Cao 
et al., 2010). Bioactive materials are typically made of compositions from the Na2O-CaO, 
MgO-P2O5-SiO2 system. The composition of the first bioglass Hench made was in weight 
percent 25% Na2O, 25% CaO, 5% P2O5 and 45% SiO2 and noted as Bioglass 45S5. Melting 
and sol- gel processing are two methods for producting glasses. Sol-gel processing has been 
successfully used in the production of a variety of materials for both biomedical and 
nonbiomedical applications (Hench, 2006; Ravarian et al., 2010). Sol-gel processing, an 
alternative to traditional melt processing of glasses, involves the synthesis of a solution (sol), 
typically composed of metal-organic and metal salt precursors followed by the formation of 
a gel by chemical reaction or aggregation, and lastly thermal treatment for drying, organic 
removal, and sometimes crystallization (Saravanapavan & Hench, 2003). Sol-gel-derived 
bioactive glasses were used because they exhibit high specific area, high osteoconductive 
properties, and a significant degradability. The sol-gel approach to making bioactive glass 
materials has produced glasses with enhanced compositional range of bioactivity. When in 
contact with body fluids or tissues, bioactive glasses develop reactive layers at their surfaces 
resulting in a chemical bond between implant and host tissue (Hench, 2006). Hench has 
described a sequence of five reactions that result in the formation of a hydroxy-carbonate 
apatite (HCA) layer on the surface of these bioactive glasses (Hench, 2006). The dissolution 
of the glass network, leading to the formation of a silica-rich gel layer and subsequent 
deposition of an apatite-like layer on the glass surface, was found to be essential steps for 
bonding of glass to living tissues both through in vivo and in vitro studies (Cao et al., 2010). 
The use of bioactive glass for load-bearing applications is restricted because of its brittleness. 
One possibility to overcome this drawback is to crystallize the glass to obtain a glass-
ceramic. Glass- ceramics are polycrystalline ceramics made by transformation of the glass 
into ceramic. The formation of glass ceramics is influenced by the nucleation and growth of 
small crystals. The nucleation of glass is carried out at temperatures much lower than the 
melting temperature. Professor Kokubo and his coworkers developed a glass-ceramic 
containing apatite and wollastonite in a glass matrix (Kokubo et al., 1986). Apatite-
wollastonite (A-W) glass-ceramic is one of the most important glass ceramics for use as a 
bone substitute. The apatite crystals form sites for bone growth; the long wollastonite 
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crystals reinforce the glass (Liu et al. 2004). Drug and growth factor loading of bioactive 
glasses and glass ceramics is possible using the sol–gel method. Ziegler et al. introduced 
Growth factors into a bioactive glass and observed an initial burst of 10%, followed by a 
delayed boost between day 3 and 8, depending on the type of growth factor (Ziegler et al., 
2002).  
3. Bone morphogenetic proteins 
Bone morphogenetic proteins (BMPs) induce new bone formation by directing 
mesenchymal stem cells. They are biologically active osteoinductive cytokines that with 
significant clinical potential. The key steps are proliferation of cells, and finally 
differentiation into cartilage and then bone. Proliferation was maximal on day 3, 
chondroblast differentiation was on day 5, and chondrocytes were on day 7. The cartilage 
hypotrophied on day 9 with vascularization and osteogenesis. On days 10 to 12 maximal 
alkaline phosphatase activity, a marker of bone formation was observed. Hematopoietic 
differentiation was observed in the ossicle on day 21. BMP were first characterized in 1965 
by Urist as a biologically activator and he has led to various studies for identification of a 
variety of growth factors that play roles in osteogenesis. The most studied of these are the 
insulin-like growth factor (IGF), epidermal growth factor (EGF), fibroblast growth factor 
(FGF), platelet-derived growth factor (PDGF), and the transforming growth factor (TGF) 
group, of which, the BMPs form a subgroup. There are 15 members of BMPs family in table 
3 and Among members of the BMPs, BMP2, 4, and 7 possess a strong ability to induce bone 
formation (Termaat et al., 2005; Nie & Wang, 2007; Calori et al., 2009).  
 
BMP designation Generic Name 
BMP1 bone morphogenetic protein 1 
BMP2 bone morphogenetic protein 2 
BMP3 bone morphogenetic protein 3 (osteogenic) 
BMP4 bone morphogenetic protein 4 
BMP5 bone morphogenetic protein 5 
BMP6 bone morphogenetic protein 6 
BMP7 bone morphogenetic protein 7 (osteogenic protein 1) 
BMP8A bone morphogenetic protein 8a 
BMP8B bone morphogenetic protein 8b (osteogenic protein 2) 
BMP9 growth differentiation factor 2 (GDF2) 
BMP10 bone morphogenetic protein 10 
BMP11 growth differentiation factor 11 (GDF11) 
BMP12 growth differentiation factor 7 (GDF7) 
BMP13 growth differentiation factor 6 (GDF6) 
BMP14 growth differentiation factor 5 (GDF5) 
BMP15 bone morphogenetic protein 15 
Table 3. The BMPs Family. (Termaat et al., 2005).  
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4. Bioactive ceramic as carrier for bone marrow cells: case study 
This experiment focuses on a tissue engineering strategy for bone regeneration using bone 
marrow carried by a bioactive ceramic scaffold. To fabricate a bioactive ceramic with porous 
configuration, the evidence of tissues ingrowth and biological responses provide obvious 
advantages in tissue-implant fixation and controlled biodegradation rate for both short-term 
and long-term implantation purposes (Klein et al., 1984; Rabiee et al., 2008c). Many 
processing technologies have been employed to obtain porous bioceramics as bone 
substuitute. The method of casting foams has shown suitability to manufacture strong and 
reliable macro-porous bioceramics that have great potential to replace bone tissue (Rabiee et 
al., 2007, 2008c). Results obtained with bone substitutes are currently less reliable than with 
autologous cancellous bone grafting which remains the preferred method for healing bone 
defects. Bone marrow stromal cells haved proved their ability to induce bone formation (Liu 
et al., 2007b). So the association of autologous bone marrow and porous bioceramic might be 
a successful hybrid biomaterial for bone substitute (Liu et al., 2007). The porous sample was 
fabricated by polyurethane foam reticulate method. The macrostructure of the scaffold was 
controlled by the porous structure of the polymer substrate. After sintering the ceramic 
resembled the polymer matrix texture, giving rise to a structure characterized by several 
macropores, whose size (100 µm <macropores size<200 µm) can assure osteoconduction 
after implantation (Fig. 1). The total porosity of the porous body was evaluated from the 
density value calculated as weight/volume and amounted to 64±5%. Details of the 
preparation method can be found in Ref. (Rabiee et al., 2009).  
 
 
Fig. 1. SEM micrograph of a macropore in sintered bioactive ceramic. 
Synthetic porous ceramic were supplied in the form of cylindrical specimens with a mean 
diameter of 3.4 ±0.5 mm and a mean length of 6.3±0.7 mm. Under general anesthesia, bone 
marrow was harvested from one medullar midshaft of the rabbit femur and diluted with 1 
www.intechopen.com
 
Biomaterials Applications for Nanomedicine 
 
10
cc of saline. The porous ceramic were immersed in the solution for 5 min before 
implantation. A cavity of 3.5 mm in diameter and 7 mm in depth was drilled manually in 
the femoral condyles under general anaesthetic conditions and antibiotic protection. After 
carefully washing with a physiological saline solution, the cavities were filled with porous 
bioactive ceramic (BC) on one side and with porous bioactive ceramic contain Bone marrow  
 
 
(A) 
  
(B) 
Fig. 2. Histological section of implants were harvested 3 months after implantation and 
stained with hematoxylin and eosin at 100x magnification. (A) bioactive ceramic, (B) 
bioactive ceramic with bone marrow cells. BC=bioactive ceramic, NB= newly formed bone. 
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(BCBM) on the other side. After 1, 2, 3 and 6 months, animals were killed by an overdose of 
thiopental sodium and the femoral condyles were removed. Experiments were performed 
according to the European Guidelines for Care and Use of Laboratory Animals (European 
Directive 86/609/CEE). During the experiment, all rabbits remained in good health and did 
not show any wound complications. No inflammatory signs or adverse tissue reaction could 
be observed. After 3 months, revealed the bridging of the BC and BCBM by host bone. Fig. 2 
shows in vivo test results after 3 months. Histological investigations show a higher presence 
of newly formed bone and a higher osteogenesis in BCBM compared to BC after 3 & 6 
months. In general, osteoblasts occurred evidently one month postoperatively, bone 
marrows began to develop in new bone tissues two months postoperatively, and bone 
tissues tended to be mature with the development of osteocytes and bone marrows over 
three months postoperatively. 
Ideally, an implant, when placed in an osseous defect, should induce a response similar to 
that of fracture healing, where by the defect is initially filled with a blood clot which is 
invaded by mesenchymal cells, osteoblasts and fibroblasts within 2 weeks, followed by 
extensive bone and osteoid formation at 6 weeks, with complete healing/repair of the 
cancellous structure by 12 weeks (Orr et al., 2001). [ 
An equivalent amount of host bone was found in the BC and BCBM treated sites (Fig. 3). No 
significant difference was seen between BCBM and BC, at month 1 and month 2, but in 
Group 3 and 6 months, osteoid surface was higher in BCBM than in BC alone (p<0.05). 
BCBM  have a stable biomechanical environment conducive to the formation of callus. Data 
from several sources show the exact effect of bone ingrowth on compressive strength and 
elastic modulus (Orr et al., 2001; Rabiee et al., 2008b). The porous implant with tissue 
ingrowth acts a composite structure. The implanted block consists of the mineral matrix of 
the block, fibrovascular tissue and bony tissue. All of these parameters effect on the 
compressive strength and modulus. 
 
 
Fig. 3. Histomorphometry of the amount of bone coverage in BC and BCBM at 1, 2, 3 and 6 
months after implantation. *p<0.05. 
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Results from mechanical compressive strength and elastic modulus of implanted specimens 
are presented in Table 4. BC specimens possessed an elastic modulus of 299±21 MPa prior to 
implantation. Elastic moduli of BC and BCBM became weaker after implantation (Table 4). 
BC moduli were significantly higher than those of the control at all time points, but no 
significant difference was apparent between BCBM and control 3 and 6 months after 
implantation. One example of the influence of a high modulus of elasticity of an implant 
material on surrounding bone is the dramatic bone loss around certain joint replacement 
prostheses. This bone loss has been attributed to the stress shielding resulting from the large 
disparity between the stiffness of the implant and the host bone (Orr et al., 2001). 
 
Time of implantation Compressive strength (MPa) Elastic modulus (MPa) 
BC BCBM BC BCBM 
Before implantatiom 6(0.5) - 299(21) - 
1 months 5.2(0.94) 5.73(1) 268(33) 232(21) 
2 months 4.8(0.9) 5.56(1.02) 232(20) 205(19) 
3 months 5(0.3) 5.96(0.62) 206(22) 188(16) 
6 months 5.1(0.5) 5.76(1.05) 195(17) 171(14) 
AC 4.7(0.6) 169(23) 
Table 4. Mechanical properties of BC and BCBM. BC= Bioactive ceramic without bone 
marrow; BCBM= Bioactive ceramic with bone marrow; AC= anatomic control. 
After implantation, BC and BCBM were partly degraded and their compressive mechanical 
properties decreased or remained at the same level. This could have resulted from two 
opposing reactions, with the matrix degrading slowly at the same time the amount of bone 
related to the reduced implant size was increasing. The first results of in vivo tests on rabbits 
showed good biocompatibility and osteointegration of the synthetic bioactive ceramic with 
bone marrow, with higher osteoconductive properties and earlier bioresorption, compared 
to similar synthetic bioactive ceramic without bone marrow samples. Bone marrow 
improved mechanical properties and bone growth. Bone ingrowth and degradation of the 
bioactive ceramic allow bone remodeling, which is a prerequisite for a good bone substitute.  
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